Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07851207) titled 'A Study to Assess Guselkumab in Participants With Moderate-to-Severe Inflammatory Bowel Disease in Real Life Italian Setting' on Sept. 25.
Study Type: Observational
Primary Sponsor: Janssen-Cilag Ltd.
Condition:
Colitis, Ulcerative
Crohn Disease
Inflammatory Bowel Diseases
Recruitment Status: Not recruiting
Date of First Enrollment: October 5, 2026
Target Sample Size: 200
To know more, visit https://clinicaltrials.gov/study/NCT07851207
Disclaimer: Curated by HT Syndication....